InMed Pharmaceuticals (INM) Operating Income (2021 - 2025)

InMed Pharmaceuticals has reported Operating Income for 5 years, with the latest figure at -$2.1 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Income rose 6.72% year-over-year to -$2.1 million; the trailing twelve-month figure through Dec 2025 stood at -$8.3 million (down 5.49% YoY), and the FY2025 full-year result was -$7.9 million, up 3.05% from the prior year.
• Operating Income for Q4 2025 stood at -$2.1 million, down from -$1.8 million in the prior quarter.
• The five-year high for Operating Income was -$485150.0 in Q2 2023, with the low at -$6.5 million in Q2 2022.
• Historically, Operating Income has averaged -$2.5 million across 5 years, with a median of -$2.2 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Income soared 92.56% — and 2024, when it slumped 319.3%.
• InMed Pharmaceuticals' Operating Income stood at -$4.3 million in 2021, then surged by 48.66% to -$2.2 million in 2022, then increased by 25.7% to -$1.6 million in 2023, then slumped by 37.03% to -$2.3 million in 2024, then grew by 6.72% to -$2.1 million in 2025.
• The last three Operating Income figures came in at -$2.1 million (Q4 2025), -$1.8 million (Q3 2025), and -$2.5 million (Q2 2025), per Business Quant data.